Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3112594rdf:typepubmed:Citationlld:pubmed
pubmed-article:3112594lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3112594lifeskim:mentionsumls-concept:C0014544lld:lifeskim
pubmed-article:3112594lifeskim:mentionsumls-concept:C0150369lld:lifeskim
pubmed-article:3112594lifeskim:mentionsumls-concept:C0037567lld:lifeskim
pubmed-article:3112594lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:3112594lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:3112594pubmed:issue1lld:pubmed
pubmed-article:3112594pubmed:dateCreated1987-8-28lld:pubmed
pubmed-article:3112594pubmed:abstractTextThe levels of sodium valproate were determined in the blood and saliva of children treated for epilepsy. The determination of drug in saliva may be a simple test checking whether the patient is taking the drugs systematically, and makes possible determination of the approximate level in the serum without blood sampling. In doubtful cases poorly responding to treatment serial monitoring of valproic acid should be undertaken.lld:pubmed
pubmed-article:3112594pubmed:languagepollld:pubmed
pubmed-article:3112594pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3112594pubmed:citationSubsetIMlld:pubmed
pubmed-article:3112594pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3112594pubmed:statusMEDLINElld:pubmed
pubmed-article:3112594pubmed:issn0028-3843lld:pubmed
pubmed-article:3112594pubmed:authorpubmed-author:Czerwi?ska-Ci...lld:pubmed
pubmed-article:3112594pubmed:authorpubmed-author:SobaniecWWlld:pubmed
pubmed-article:3112594pubmed:authorpubmed-author:Wro?skiBBlld:pubmed
pubmed-article:3112594pubmed:authorpubmed-author:SzczepaniakLLlld:pubmed
pubmed-article:3112594pubmed:issnTypePrintlld:pubmed
pubmed-article:3112594pubmed:volume21lld:pubmed
pubmed-article:3112594pubmed:ownerNLMlld:pubmed
pubmed-article:3112594pubmed:authorsCompleteYlld:pubmed
pubmed-article:3112594pubmed:pagination1-5lld:pubmed
pubmed-article:3112594pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:meshHeadingpubmed-meshheading:3112594-...lld:pubmed
pubmed-article:3112594pubmed:articleTitle[Monitoring sodium valproate treatment of epilepsy in the development years].lld:pubmed
pubmed-article:3112594pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3112594pubmed:publicationTypeEnglish Abstractlld:pubmed